Market Overview

Goldman Sachs Sees 8% Upside At Dr. Reddy's

Goldman Sachs Sees 8% Upside At Dr. Reddy's

Goldman Sachs has started Dr.Reddy's Laboratories Ltd (ADR) (NYSE: RDY) with a Neutral rating; its price target of Rs.3,334.00 represents an upside of 8 percent.

"[W]e believe upside from current levels will depend more on when the company can resolve cGMP issues at warning letter plants (Srikakulam, Miryalaguda, Duvvuda; 12 percent–15 percent of FY16E sales), than on its pipeline in which launches have been consequently delayed," analyst Shyam Srinivasan wrote in a note.

Related Link: PrimaBioMed Jumps 10% As Company Receives Japanese Patent Grant

Notably, the analyst said the company's key generics, like gXeloda, gCopaxone and gGleevec (accounting for 4 percent of FY16E–FY19E sales), will now launch later than originally expected. According to Srinivasan, gGleevec, gXeloda, gZevavod and gDiprivan should collectively contribute above US$160 million in sales over FY17–FY18.

Although the analyst is "encouraged by the recent in-licensing of Ph II psoriasis molecule XP23829," he said, "There remain more hurdles to cross before commercialization, which should take at least two years from now, in a best-case scenario."

Moreover, the warning letter on the plants remains a key overhang on the stock, and the analyst said he expects a resolution could take until late FY17.

At time of writing, ADRs of Dr.Reddy's were down 1.73 percent to $44.81.

Latest Ratings for RDY

Sep 2019UpgradesUnderperformOutperform
Jun 2019Initiates Coverage OnEqual-Weight
May 2019DowngradesOverweightEqual-Weight

View More Analyst Ratings for RDY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Emerging Markets Price Target Initiation Top Stories Markets Best of Benzinga


Related Articles (RDY)

View Comments and Join the Discussion!

Here's How Baker Hughes Will Benefit From A Merger It Never Wanted In The First Place

Is Amazon Unstoppable? Gene Munster Thinks So